Kalkman, LC; Hanscheid, T; Krishna, S; Kremsner, PG; Grobusch, MP
(2022)
Antimalarial treatment in infants.
Expert Opin Pharmacother, 23 (15).
pp. 1711-1726.
ISSN 1744-7666
https://doi.org/10.1080/14656566.2022.2130687
SGUL Authors: Krishna, Sanjeev
Abstract
INTRODUCTION: Malaria in infants is common in high-transmission settings, especially in infants >6 months. Infants undergo physiological changes impacting pharmacokinetics and pharmacodynamics of anti-malarial drugs and, consequently, the safety and efficacy of malaria treatment. Yet, treatment guidelines and evidence on pharmacological interventions for malaria often fail to address this vulnerable age group. This review aims to summarize the available data on anti-malarial treatment in infants. AREAS COVERED: The standard recommended treatments for severe and uncomplicated malaria are generally safe and effective in infants. However, infants have an increased risk of drug-related vomiting and have distinct pharmacokinetic parameters of antimalarials compared with older patients. These include larger volumes of distribution, higher clearance rates, and immature enzyme systems. Consequently, infants with malaria may be at increased risk of treatment failure and drug toxicity. EXPERT OPINION: Knowledge expansion to optimize treatment can be achieved by including more infants in antimalarial drug trials and by reporting separately on treatment outcomes in infants. Additional evidence on the efficacy, safety, tolerability, acceptability, and effectiveness of ACTs in infants is needed, as well as population pharmacokinetics studies on antimalarials in the infant population.
Item Type: |
Article
|
Additional Information: |
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
Keywords: |
Malaria, infants, pharmacodynamics, pharmacokinetics, treatment, Infant, Humans, Antimalarials, Malaria, Malaria, Falciparum, Humans, Malaria, Malaria, Falciparum, Antimalarials, Infant, Malaria, treatment, infants, pharmacodynamics, pharmacokinetics, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
Expert Opin Pharmacother |
ISSN: |
1744-7666 |
Language: |
eng |
Dates: |
Date | Event |
---|
5 October 2022 | Published | 29 September 2022 | Published Online |
|
Publisher License: |
Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 |
PubMed ID: |
36174125 |
Web of Science ID: |
WOS:000864805200001 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/114978 |
Publisher's version: |
https://doi.org/10.1080/14656566.2022.2130687 |
Statistics
Item downloaded times since 10 Nov 2022.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |